MY139296A - CRYSTALLINE ß2 ADRENERGIC RECEPTOR AGONIST - Google Patents
CRYSTALLINE ß2 ADRENERGIC RECEPTOR AGONISTInfo
- Publication number
- MY139296A MY139296A MYPI20032804A MYPI20032804A MY139296A MY 139296 A MY139296 A MY 139296A MY PI20032804 A MYPI20032804 A MY PI20032804A MY PI20032804 A MYPI20032804 A MY PI20032804A MY 139296 A MY139296 A MY 139296A
- Authority
- MY
- Malaysia
- Prior art keywords
- crystalline
- adrenergic receptor
- receptor agonist
- pharmaceutical compositions
- salt form
- Prior art date
Links
- 239000000048 adrenergic agonist Substances 0.000 title abstract 2
- 229940126157 adrenergic receptor agonist Drugs 0.000 title abstract 2
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 title 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 150000003839 salts Chemical group 0.000 abstract 2
- 108060003345 Adrenergic Receptor Proteins 0.000 abstract 1
- 102000017910 Adrenergic receptor Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/04—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reaction of ammonia or amines with olefin oxides or halohydrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
- C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39892802P | 2002-07-26 | 2002-07-26 | |
| US39867802P | 2002-07-26 | 2002-07-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY139296A true MY139296A (en) | 2009-09-30 |
Family
ID=31191218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20032804A MY139296A (en) | 2002-07-26 | 2003-07-25 | CRYSTALLINE ß2 ADRENERGIC RECEPTOR AGONIST |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20050075271A1 (enExample) |
| EP (1) | EP1532104A1 (enExample) |
| JP (1) | JP2005533860A (enExample) |
| CN (1) | CN100491342C (enExample) |
| AR (1) | AR040661A1 (enExample) |
| AU (1) | AU2003259229A1 (enExample) |
| BR (1) | BR0312975A (enExample) |
| CA (1) | CA2493128A1 (enExample) |
| MY (1) | MY139296A (enExample) |
| TW (1) | TW200409746A (enExample) |
| WO (1) | WO2004011416A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA73965C2 (en) * | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| TW200510277A (en) * | 2003-05-27 | 2005-03-16 | Theravance Inc | Crystalline form of β2-adrenergic receptor agonist |
| TW200526547A (en) * | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists |
| TW200531692A (en) * | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| EP1730104A1 (en) | 2004-04-02 | 2006-12-13 | Glaxo Group Limited | Chemical process and new crystalline form |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| EP1786762A2 (en) * | 2004-09-10 | 2007-05-23 | Theravance, Inc. | Amidine substituted aryl aniline compounds |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| WO2006051373A1 (en) * | 2004-11-12 | 2006-05-18 | Pfizer Limited | Compounds for the treatment of diseases |
| WO2006066907A1 (en) * | 2004-12-21 | 2006-06-29 | Glaxo Group Limited | Pharmaceutical formulations |
| ES2265276B1 (es) | 2005-05-20 | 2008-02-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| BRPI0711558A2 (pt) | 2006-05-04 | 2011-11-08 | Boeringer Ingelheim Internat Gmbh | polimorfos |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| BRPI0816904B8 (pt) | 2007-09-19 | 2021-12-07 | Ambit Biosciences Corp | Forma cristalna b da forma sólida do sal de bis-hcl, composição farmacêutica, e, uso de uma forma sólida |
| JP5325517B2 (ja) * | 2007-10-12 | 2013-10-23 | 住友化学株式会社 | ジベンゾオキセピン化合物の精製方法 |
| JP2009102249A (ja) * | 2007-10-22 | 2009-05-14 | Sumitomo Chemical Co Ltd | ジベンゾオキセピン化合物の結晶の製造方法 |
| PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
| AU2009290911A1 (en) | 2008-09-10 | 2010-03-18 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| EP2382216A1 (en) | 2008-12-23 | 2011-11-02 | Boehringer Ingelheim International GmbH | Salt forms of organic compound |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| EP2228368A1 (en) | 2009-03-12 | 2010-09-15 | Almirall, S.A. | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one |
| WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
| EA034869B1 (ru) | 2009-11-27 | 2020-03-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин |
| MX341025B (es) | 2010-05-05 | 2016-08-04 | Boehringer Ingelheim Int Gmbh * | Terapia de combinacion. |
| PH12012502524A1 (en) | 2010-06-24 | 2014-02-10 | Boehringer Ingelheim Int | Diabetes therapy |
| GB201016912D0 (en) | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| EP3517539B1 (en) | 2011-07-15 | 2022-12-14 | Boehringer Ingelheim International GmbH | Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes |
| EP2578570A1 (en) | 2011-10-07 | 2013-04-10 | Almirall, S.A. | Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis. |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
| PL3517541T3 (pl) | 2012-05-08 | 2020-12-28 | Nicox Ophthalmics, Inc. | Postać polimorficzna propionianu flutykazonu |
| US8765725B2 (en) | 2012-05-08 | 2014-07-01 | Aciex Therapeutics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| US20130303554A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in sirs and/or sepsis |
| JP6224084B2 (ja) | 2012-05-14 | 2017-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| US9815865B2 (en) | 2013-01-07 | 2017-11-14 | Nicox Ophthalmics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
| CN109310697A (zh) | 2016-06-10 | 2019-02-05 | 勃林格殷格翰国际有限公司 | 利格列汀和二甲双胍的组合 |
| TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL63968A (en) * | 1980-10-01 | 1985-10-31 | Glaxo Group Ltd | Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it |
| HU196775B (en) * | 1986-08-05 | 1989-01-30 | Richter Gedeon Vegyeszet | Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances |
| US5225183A (en) * | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| DK0679088T3 (da) * | 1992-09-29 | 2002-10-28 | Inhale Therapeutic Syst | Pulmonal levering af aktive fragmenter af parathyreoideaea hormon |
| EP0735884B1 (en) * | 1993-12-20 | 2000-04-26 | Minnesota Mining And Manufacturing Company | Flunisolide aerosol formulations |
| EP1366777B1 (en) * | 1995-04-14 | 2005-06-15 | SmithKline Beecham Corporation | Metered dose inhaler for salmeterol |
| US6040344A (en) * | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
| GB9713819D0 (en) * | 1997-06-30 | 1997-09-03 | Glaxo Group Ltd | Method of reducing the systemic effects of compounds |
| US6362371B1 (en) * | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
| US6683115B2 (en) * | 1999-06-02 | 2004-01-27 | Theravance, Inc. | β2-adrenergic receptor agonists |
| OA11558A (en) * | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| UA73965C2 (en) * | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
| US6667344B2 (en) * | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| TWI249515B (en) * | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| US6769398B2 (en) * | 2002-06-04 | 2004-08-03 | Ford Global Technologies, Llc | Idle speed control for lean burn engine with variable-displacement-like characteristic |
-
2003
- 2003-07-22 AR AR20030102632A patent/AR040661A1/es unknown
- 2003-07-22 TW TW092119979A patent/TW200409746A/zh unknown
- 2003-07-25 US US10/627,555 patent/US20050075271A1/en not_active Abandoned
- 2003-07-25 CN CNB038179296A patent/CN100491342C/zh not_active Expired - Fee Related
- 2003-07-25 CA CA002493128A patent/CA2493128A1/en not_active Abandoned
- 2003-07-25 AU AU2003259229A patent/AU2003259229A1/en not_active Abandoned
- 2003-07-25 EP EP03771813A patent/EP1532104A1/en not_active Withdrawn
- 2003-07-25 BR BR0312975-6A patent/BR0312975A/pt not_active IP Right Cessation
- 2003-07-25 JP JP2004524793A patent/JP2005533860A/ja active Pending
- 2003-07-25 MY MYPI20032804A patent/MY139296A/en unknown
- 2003-07-25 WO PCT/US2003/023214 patent/WO2004011416A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004011416A1 (en) | 2004-02-05 |
| JP2005533860A (ja) | 2005-11-10 |
| CN100491342C (zh) | 2009-05-27 |
| CN1671650A (zh) | 2005-09-21 |
| EP1532104A1 (en) | 2005-05-25 |
| AR040661A1 (es) | 2005-04-13 |
| CA2493128A1 (en) | 2004-02-05 |
| US20050075271A1 (en) | 2005-04-07 |
| BR0312975A (pt) | 2005-06-14 |
| TW200409746A (en) | 2004-06-16 |
| AU2003259229A1 (en) | 2004-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05012678A (es) | Forma cristalina del agonista del receptor adrenergico beta2. | |
| BR0312975A (pt) | Forma cristalina de agonista de receptor adrenérgico ß2 | |
| MY138220A (en) | ARYL ANILINE ß2 ADRENERGIC RECEPTOR AGONISTS | |
| AP1822A (en) | Substituted pyridinones as modulators of P38 MAP kinase. | |
| IL183160A0 (en) | Indazole-carboxamide compounds | |
| TW200517388A (en) | Thiazole derivatives as cannabinoid receptor modulators | |
| MXPA05009367A (es) | Antagonistas del receptor opioide. | |
| MY147640A (en) | Bicyclic amides as kinase inhibitors | |
| MXPA05007181A (es) | Cristales de la hormona de crecimiento humano y metodos para prepararlos. | |
| TW200420541A (en) | Crystalline forms | |
| WO2005030678A3 (en) | AMINO-SUBSTITUTED ETHYLAMINO β2 ADRENERGIC RECEPTOR AGONISTS | |
| WO2006031556A3 (en) | Amidine substituted aryl aniline compounds | |
| TNSN04203A1 (en) | Benzoxazinone-derived compounds, their preparation and use as medicaments | |
| DE602004024383D1 (de) | Kristalline formen eines arylanilin-beta-2-adrenergenrezeptor-agonists | |
| WO2006052889A3 (en) | Quinolinone-carboxamide compounds | |
| MXPA05013151A (es) | 3-fluoro-piperidinas como antagonistas de n-metil-d-aspartato/nr2b. | |
| IL176546A0 (en) | Imidazoline derivatives having cb1-antagonistic activity | |
| TW200630352A (en) | Chemical compounds | |
| IL145645A0 (en) | N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists | |
| TW200716607A (en) | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | |
| TW200503785A (en) | Dosage form containing (S)-pantoprazole as active ingredient | |
| IL165220A0 (en) | Novel compounds, their use and preparation | |
| TW200640921A (en) | Crystalline form of an indazole-carboxamide compound | |
| MY179041A (en) | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | |
| UA81405C2 (en) | Substituted pyridinones as modulators of p38 map kinase |